ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1

Oncogene

Volumn 29, Issue 22, 2010, Pages 3307-3312

  Krapf, G ^a   Kaindl, U ^a   Kilbey, A ^b   Fuka, G ^a   Inthal, A ^a   Joas, R ^a   Mann, G ^c   Neil, J C ^b   Haas, O A ^c   Panzer Grumayer E R ^a,c  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b Faculty of Veterinary Medicine   (United Kingdom)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

21); Acute lymphoblastic leukemia; ETV6 RUNX1; Mitotic checkpoint MAD2L1; T(12; Tetraploidy

Indexed keywords

PROTEIN MAD2L1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; CELL CYCLE PROTEIN; MAD2L1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN MAD2; REPRESSOR PROTEIN; TEL-AML1 FUSION PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA CONTENT; FUSION GENE; GENE ACTIVATION; GENE FUSION; HUMAN; HUMAN CELL; MITOSIS INDEX; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; REPORTER GENE; TETRAPLOIDY; TRIPLOIDY; TRISOMY 21; GENE REARRANGEMENT; GENETICS; KARYOTYPING; MITOSIS; PROMOTER REGION; TUMOR CELL LINE;

CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE FUSION; GENE REARRANGEMENT; HUMANS; KARYOTYPING; MITOSIS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; MAD2 PROTEINS;

MURINAE;

EID: 77953231430     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.53     Document Type: Article

References (32)

1. Attarbaschi A, Mann G, Konig M, Dworzak MN, Trebo MM, Muhlegger N et al. (2004). Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia 18: 1611-1616.
2. Attarbaschi A, Mann G, Konig M, Steiner M, Dworzak MN, Gadner H et al. (2006). Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases. Genes Chromosomes Cancer 45: 608-611.
3. Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE. (2007). A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 109: 3963-3971.
4. Diakos C, Krapf G, Gerner C, Inthal A, Lemberger C, Ban J et al. (2007). RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein-and survivin-dependent mechanism for survival. Blood 109: 2607-2610.
5. Fang Y, Liu T, Wang X, Yang YM, Deng H, Kunicki J et al. (2006). BubR1 is involved in regulation of DNA damage responses. Oncogene 25: 3598-3605.
6. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D et al. (2009). The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 119: 826-836.
7. Friedman AD. (1999). Leukemogenesis by CBF oncoproteins. Leukemia 13: 1932-1942.
8. Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T et al. (2008). Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 452: 365-369.
9. Ha GH, Baek KH, Kim HS, Jeong SJ, Kim CM, McKeon F et al. (2007). p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res 67: 7155-7164.
10. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A et al. (1996). The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16: 1349-1355.
11. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. (2008). Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319: 336-339.
12. Kops GJ, Weaver BA, Cleveland DW. (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785.
13. Li Z, Yan J, Matheny CJ, Corpora T, Bravo J, Warren AJ et al. (2003). Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem 278: 33088-33096.
14. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher IF, Friedman AD. (2000). Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF\a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 19: 2695-2703.
15. Michel L, Benezra R, Diaz-Rodriguez E. (2004). MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword. Cell Cycle 3: 990-992.
16. Morrow M, Samanta A, Kioussis D, Brady HJ, Williams O. (2007). TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene 26: 4404-4414.
17. Perez de Castro I, de Carcer G, Malumbres M. (2007). A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28: 899-912.
18. Peters JM. (2007). Cell biology: the checkpoint brake relieved. Nature 446: 868-869.
19. Pines J. (2006). Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 16: 55-63.
20. Pui CH, Relling MV, Downing JR. (2004). Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548.
21. Raimondi SC, Zhou Y, Shurtleff SA, Rubnitz JE, Pui CH, Behm FG. (2006). Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet 169: 50-57.
22. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK et al. (2003). Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102: 2951-2959. (Pubitemid 37248870)
23. Roudaia L, Cheney MD, Manuylova E, Chen W, Morrow M, Park S et al. (2009). CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood 113: 3070-3079.
24. Sasaki K, Nakamura Y, Maki K, Waga K, Nakamura F, Arai H et al. (2004). Functional analysis of a dominant-negative DeltaETS TEL/ETV6 isoform. Biochem Biophys Res Commun 317: 1128-1137.
25. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. (1999). Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23: 166-175.
26. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW et al. (2007). Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11: 9-23.
27. Speck NA, Gilliland DG. (2002). Core-binding factors in haematopoi-esis and leukaemia. Nat Rev Cancer 2: 502-513.
28. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR et al. (2000). Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 275: 3438-3445.
29. Weaver BA, Cleveland DW. (2005). Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12.
30. Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, Peters G et al. (2009). RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 28: 2502-2512.
31. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E et al. (2008). Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 27: 5856-5866.
32. Zelent A, Greaves M, Enver T. (2004). Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lympho-blastic leukaemia. Oncogene 23: 4275-4283.